Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2017 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
September 27, 2017 08:00 ET | Source: aTyr Pharma Inc.

aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society

SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
August 14, 2017 16:05 ET | Source: aTyr Pharma Inc.

aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline

– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
May 11, 2017 16:05 ET | Source: aTyr Pharma Inc.

aTyr Pharma Announces First Quarter 2017 Operating Results

– Announced Promising Top-Line Results from ResolarisTM Phase 1b/2 Trial in Early Onset FSHD –– Preclinical Data from StalarisTM Program to be Presented at American Thoracic Society...
April 24, 2017 08:00 ET | Source: aTyr Pharma Inc.

aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting

- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B...